Edwards Lifesciences (EW) Amortization of Deferred Charges (2019 - 2021)

Edwards Lifesciences' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $7.1 million for Q4 2021.

• In Q4 2021, Amortization of Deferred Charges fell 5.33% year-over-year to $7.1 million; the TTM figure through Dec 2021 stood at $28.5 million (up 1.06% YoY), while the FY2021 annual figure was $28.5 million, up 1.06% from the prior year.
• Amortization of Deferred Charges was $7.1 million for Q4 2021 at Edwards Lifesciences, roughly flat from $7.1 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $7.5 million in Q4 2020 to a low of $5.7 million in Q1 2019.
• Historically, Amortization of Deferred Charges has averaged $6.8 million across 3 years, with a median of $7.0 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Amortization of Deferred Charges climbed 17.54% in 2020, then decreased 5.33% in 2021.
• A 3-year view of Amortization of Deferred Charges shows it stood at $6.6 million in 2019, then climbed by 13.64% to $7.5 million in 2020, then fell by 5.33% to $7.1 million in 2021.
• The last three Amortization of Deferred Charges figures came in at $7.1 million (Q4 2021), $7.1 million (Q3 2021), and $7.0 million (Q2 2021), per Business Quant data.